Guselkumab for ulcerative colitis in Chinese patients
Part of Digestive system clinical trials.
This study tracks how well guselkumab (Tremfya) works in real-world Chinese patients with moderate to severe ulcerative colitis who haven't tried advanced therapies before. It helps doctors understand how the drug performs outside of controlled trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe ulcerative colitis (UC), meaning your symptoms are active enough to need advanced treatment.
- You have never taken advanced therapies like biologics or JAK inhibitors for your UC.
- Your doctor has decided to start you on guselkumab (Tremfya) as your first advanced treatment.
- You are not currently in a severe UC flare that needs immediate surgery or hospitalization.
- You have not had your colon removed or had pouch surgery.
- You are willing to sign a consent form allowing your medical data to be reviewed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
This study looks at how well guselkumab works for people with moderate to severe Crohn's disease or ulcerative colitis when used as part of regular treatment. It gathers information from real patients to see how the drug performs outside of a research setting.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study tracks how well guselkumab (Tremfya) works in real-life for people with inflammatory bowel disease in Germany. If you are starting this treatment, researchers will watch your progress and ask you to fill out simple surveys about your symptoms.
This study tracks how well guselkumab (a biologic medication that blocks IL-23, a protein that drives inflammation) works for moderate-to-severe ulcerative colitis or Crohn's disease in everyday clinical practice. Researchers want to understand long-term benefits and safety in real patients.
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
Hear when a new Colitis, Ulcerative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.